<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00431951</url>
  </required_header>
  <id_info>
    <org_study_id>ST-246 RD PHS 1</org_study_id>
    <secondary_id>DMID 06-0080</secondary_id>
    <nct_id>NCT00431951</nct_id>
  </id_info>
  <brief_title>Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers</brief_title>
  <acronym>SIGA-246-002</acronym>
  <official_title>Double-blind, Randomized, Placebo-controlled, Escalating, Multiple-dose, Phase I Trial to Assess Safety, Tolerability and Pharmacokinetics of ST-246 Administered as a Single Daily Dose for 21 Days in Healthy, Non-fasted Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SIGA Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>SIGA Technologies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to assess the safety, tolerability, and pharmacokinetics of a
      single, daily, oral dose of ST-246 (either 250, 400 or 800mg) administered for 21 days to 30
      healthy, fed volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a double-blind, placebo-controlled, dose-escalating, multiple-dose study of orally
      administered ST-246 to 30 healthy volunteers ages 18-50 years, randomized to receive either
      active drug (8 subjects) or placebo (2 subjects) in 1 of 3 dosing groups (250, 400 or 800mg
      groups). Each dose group of 10 was divided into two cohorts of 5 subjects (4 active and 1
      placebo). The first cohort was dosed approximately 4-8 weeks before the second cohort of each
      dose group. Dose groups completed the study treatment approximately 5 weeks prior to the
      start of the following dose group. Study procedures included several overnight stays, medical
      history/exam, laboratory testing done by blood draw, and electrocardiograms.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Study Participants Who Tolerated ST-246 (250, 400 or 800mg) as Determined by Changes in Safety Parameters, According to the Division of Acquired Immunodeficiency Syndrome (DAIDS) Adverse Events (AE) Grading Table</measure>
    <time_frame>Days 1, 6, 14-16, 21-24, 28-31, and 51-53</time_frame>
    <description>Evaluated safety parameters included:
physical examination/vital signs
electrocardiograms (heart rate, PR interval, QRS duration, QT interval, and QTc Bazett)
laboratory safety tests (hematology, chemistry, urinalysis)
adverse events (AEs) For a)-c), statistical values (mean, standard deviation, median, minimum, maximum) and changes from baseline (Day 1 pre-dose) to each time-point, were compared to laboratory normal reference ranges. If values for a)-d) were a Grade 3 or higher (in DAIDS AE Table)and ST-246-related, they were considered severe and significant, respectively.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Pharmacokinetic Parameters to Assess Interventions: Cmax</measure>
    <time_frame>Day 1</time_frame>
    <description>Cmax: Maximum drug concentration in plasma determined directly from individual concentration-time data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Pharmacokinetic Parameters to Assess Interventions: Cmax</measure>
    <time_frame>Day 6</time_frame>
    <description>Cmax: Maximum drug concentration in plasma determined directly from individual concentration-time data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Pharmacokinetic Parameters to Assess Interventions: Cmax</measure>
    <time_frame>Day 21</time_frame>
    <description>Cmax: Maximum drug concentration in plasma determined directly from individual concentration-time data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Pharmacokinetic Parameters to Assess Interventions: Tmax</measure>
    <time_frame>Day 1</time_frame>
    <description>Tmax: Time to reach maximum drug concentration in plasma calculated from [plasma] versus time profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Pharmacokinetic Parameters to Assess Interventions: Tmax</measure>
    <time_frame>Day 6</time_frame>
    <description>Tmax: Time to reach maximum drug concentration in plasma calculated from [plasma] versus time profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Pharmacokinetic Parameters to Assess Interventions: Tmax</measure>
    <time_frame>Day 21</time_frame>
    <description>Tmax: Time to reach maximum drug concentration in plasma calculated from [plasma] versus time profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Pharmacokinetic Parameters to Assess Interventions: t½</measure>
    <time_frame>Day 21</time_frame>
    <description>t½: Observed terminal elimination half-life determined after the last dose on Day 21</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Pharmacokinetic Parameters to Assess Interventions: AUCtau</measure>
    <time_frame>Day 1</time_frame>
    <description>AUCtau: Area under the plasma concentration-time curve for each dosing interval (from time 0 to 24 hours sample) determined using the linear trapezoidal rule</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Pharmacokinetic Parameters to Assess Interventions: AUCtau</measure>
    <time_frame>Day 6</time_frame>
    <description>AUCtau: Area under the plasma concentration-time curve for each dosing interval (from time 0 to 24 hours sample) determined using the linear trapezoidal rule</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Pharmacokinetic Parameters to Assess Interventions: AUCtau</measure>
    <time_frame>Day 21</time_frame>
    <description>AUCtau: Area under the plasma concentration-time curve for each dosing interval (from time 0 to 24 hours sample) determined using the linear trapezoidal rule</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Pharmacokinetic Parameters to Assess Interventions: Ae(0-24)</measure>
    <time_frame>Day 1</time_frame>
    <description>Ae(0-24): Cumulative amount of drug excreted unchanged in urine over 24 hours (three 8-hour collection periods), determined on Days 1 and 21</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Pharmacokinetic Parameters to Assess Interventions: Ae(0-24)</measure>
    <time_frame>Day 21</time_frame>
    <description>Ae(0-24): Cumulative amount of drug excreted unchanged in urine over 24 hours (three 8-hour collection periods), determined on Days 1 and 21</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>ST-246</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>250 mg, 400 mg or 800 mg of ST-246 given once daily for 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to match ST-246</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ST-246</intervention_name>
    <description>250 mg, 400 mg or 800 mg capsules given once daily for 21 days</description>
    <arm_group_label>ST-246</arm_group_label>
    <other_name>Tecovirimat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsules to match experimental drug</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Placebo to match ST-246</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Subject Inclusion Criteria:

          -  Healthy volunteers

          -  Ability to Consent

          -  Not taking any other medication

          -  Adequate venous access

          -  Using adequate birth control

        Subject Exclusion Criteria:

          -  Inability to swallow study medication.

          -  Pregnant or breastfeeding

          -  Received experimental drug within 30 days of study entry or will participate in any
             experimental study during the study period.

          -  Current drug abuse, alcohol abuse, or homelessness.

          -  Taking concomitant medication

          -  Lactose Intolerance

          -  Medical condition; e.g., asthma, diabetes, thyroid disease, angioedema, BMI &gt;35 or
             &lt;18, hypertension, bleeding disorder, malignancy, seizure, neutropenia, Hepatitis B or
             C, HIV or AIDS.

          -  Any condition, occupational reason or other responsibility that, in the judgment of
             the Investigator, would jeopardize the safety or rights of a volunteer, or render the
             subject unable to comply with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas C Marbury, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orlando Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orlando Clinical Research</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2007</study_first_submitted>
  <study_first_submitted_qc>February 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2007</study_first_posted>
  <results_first_submitted>May 29, 2009</results_first_submitted>
  <results_first_submitted_qc>April 16, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 7, 2010</results_first_posted>
  <last_update_submitted>July 25, 2017</last_update_submitted>
  <last_update_submitted_qc>July 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Volunteers</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at one site, Orlando Clinical Research Center, Orlando, FL. The study was conducted in healthy volunteers from the site's database.</recruitment_details>
      <pre_assignment_details>After a 28-day screening and 1-day enrollment period, study drug was administered on Day 1. Ten participants (8 drug:2 placebo) were randomized in each of three dosing groups (250, 400, and 800 mg ST-246). Each group was divided into 2 cohorts of 5 subjects (4 drug:1 placebo), with one cohort receiving drug 4-8 weeks before the other cohort.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ST-246 250 mg</title>
          <description>250 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days.</description>
        </group>
        <group group_id="P2">
          <title>ST-246 400mg</title>
          <description>400 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days. Blood and urine samples for PK taken on Days 1, 6, and 21.</description>
        </group>
        <group group_id="P3">
          <title>ST-246 800 mg</title>
          <description>800 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days. Blood and urine samples for PK taken on Days 1, 6, and 21.</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo given as a single daily oral dose for 21 days to 6 subjects, to match ST-246 doses (2 patients for each dose equivalent). Blood and urine samples for PK taken on Days 1, 6, and 21.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Inability to follow study procedures</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ST-246 250 mg</title>
          <description>250 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days.</description>
        </group>
        <group group_id="B2">
          <title>ST-246 400mg</title>
          <description>400 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days. Blood and urine samples for PK taken on Days 1, 6, and 21.</description>
        </group>
        <group group_id="B3">
          <title>ST-246 800 mg</title>
          <description>800 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days. Blood and urine samples for PK taken on Days 1, 6, and 21.</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo given as a single daily oral dose for 21 days to 6 subjects, to match ST-246 doses (2 patients for each dose equivalent). Blood and urine samples for PK taken on Days 1, 6, and 21.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.5" spread="8.2"/>
                    <measurement group_id="B2" value="27.6" spread="7.8"/>
                    <measurement group_id="B3" value="37.5" spread="7.6"/>
                    <measurement group_id="B4" value="34.8" spread="8.9"/>
                    <measurement group_id="B5" value="33.9" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Study Participants Who Tolerated ST-246 (250, 400 or 800mg) as Determined by Changes in Safety Parameters, According to the Division of Acquired Immunodeficiency Syndrome (DAIDS) Adverse Events (AE) Grading Table</title>
        <description>Evaluated safety parameters included:
physical examination/vital signs
electrocardiograms (heart rate, PR interval, QRS duration, QT interval, and QTc Bazett)
laboratory safety tests (hematology, chemistry, urinalysis)
adverse events (AEs) For a)-c), statistical values (mean, standard deviation, median, minimum, maximum) and changes from baseline (Day 1 pre-dose) to each time-point, were compared to laboratory normal reference ranges. If values for a)-d) were a Grade 3 or higher (in DAIDS AE Table)and ST-246-related, they were considered severe and significant, respectively.</description>
        <time_frame>Days 1, 6, 14-16, 21-24, 28-31, and 51-53</time_frame>
        <population>Post-screening, 30 healthy subjects were randomized into three active drug groups with 8 subjects each, and one placebo group with 6 subjects. A total of 7 withdrawals during the entire study were due to inability to follow procedure (4), lost to follow-up (1), requested due to concomitant medication (1), and an adverse event (1)</population>
        <group_list>
          <group group_id="O1">
            <title>ST-246 250 mg</title>
            <description>250 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days.</description>
          </group>
          <group group_id="O2">
            <title>ST-246 400mg</title>
            <description>400 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days.</description>
          </group>
          <group group_id="O3">
            <title>ST-246 800 mg</title>
            <description>800 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo given as a single daily oral dose for 21 days to 6 subjects, to match ST-246 doses (2 patients for each dose equivalent).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Study Participants Who Tolerated ST-246 (250, 400 or 800mg) as Determined by Changes in Safety Parameters, According to the Division of Acquired Immunodeficiency Syndrome (DAIDS) Adverse Events (AE) Grading Table</title>
          <description>Evaluated safety parameters included:
physical examination/vital signs
electrocardiograms (heart rate, PR interval, QRS duration, QT interval, and QTc Bazett)
laboratory safety tests (hematology, chemistry, urinalysis)
adverse events (AEs) For a)-c), statistical values (mean, standard deviation, median, minimum, maximum) and changes from baseline (Day 1 pre-dose) to each time-point, were compared to laboratory normal reference ranges. If values for a)-d) were a Grade 3 or higher (in DAIDS AE Table)and ST-246-related, they were considered severe and significant, respectively.</description>
          <population>Post-screening, 30 healthy subjects were randomized into three active drug groups with 8 subjects each, and one placebo group with 6 subjects. A total of 7 withdrawals during the entire study were due to inability to follow procedure (4), lost to follow-up (1), requested due to concomitant medication (1), and an adverse event (1)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Pharmacokinetic Parameters to Assess Interventions: Cmax</title>
        <description>Cmax: Maximum drug concentration in plasma determined directly from individual concentration-time data</description>
        <time_frame>Day 1</time_frame>
        <population>Post-screening, 30 healthy subjects were randomized on Day 1 into three active drug groups with 8 subjects each and one placebo group with 6 subjects</population>
        <group_list>
          <group group_id="O1">
            <title>ST-246 250 mg</title>
            <description>250 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days. Blood and urine samples for PK taken on Days 1, 6, and 21.</description>
          </group>
          <group group_id="O2">
            <title>ST-246 400mg</title>
            <description>400 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days. Blood and urine samples for PK taken on Days 1, 6, and 21.</description>
          </group>
          <group group_id="O3">
            <title>ST-246 800 mg</title>
            <description>800 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days. Blood and urine samples for PK taken on Days 1, 6, and 21.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo given as a single daily oral dose to 6 subjects for 21 days, to match ST-246 doses (2 patients for each dose equivalent). Blood and urine samples for PK taken on Days 1, 6, and 21.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Pharmacokinetic Parameters to Assess Interventions: Cmax</title>
          <description>Cmax: Maximum drug concentration in plasma determined directly from individual concentration-time data</description>
          <population>Post-screening, 30 healthy subjects were randomized on Day 1 into three active drug groups with 8 subjects each and one placebo group with 6 subjects</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="985" spread="346"/>
                    <measurement group_id="O2" value="1392" spread="411"/>
                    <measurement group_id="O3" value="2279" spread="395"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Pharmacokinetic Parameters to Assess Interventions: Cmax</title>
        <description>Cmax: Maximum drug concentration in plasma determined directly from individual concentration-time data</description>
        <time_frame>Day 6</time_frame>
        <population>Post-screening, 30 healthy subjects were randomized into three active drug groups with 8 subjects each and one placebo group with 6 subjects. By Day 6 there were 3 (out of 7 total) withdrawals from the study due to inability to follow procedure (2; 800mg and placebo groups), and requested due to concomitant medication (1; 400mg group)</population>
        <group_list>
          <group group_id="O1">
            <title>ST-246 250 mg</title>
            <description>250 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days.</description>
          </group>
          <group group_id="O2">
            <title>ST-246 400mg</title>
            <description>400 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days.</description>
          </group>
          <group group_id="O3">
            <title>ST-246 800 mg</title>
            <description>800 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo given as a single daily oral dose for 21 days to 6 subjects, to match ST-246 doses (2 patients for each dose equivalent).</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Pharmacokinetic Parameters to Assess Interventions: Cmax</title>
          <description>Cmax: Maximum drug concentration in plasma determined directly from individual concentration-time data</description>
          <population>Post-screening, 30 healthy subjects were randomized into three active drug groups with 8 subjects each and one placebo group with 6 subjects. By Day 6 there were 3 (out of 7 total) withdrawals from the study due to inability to follow procedure (2; 800mg and placebo groups), and requested due to concomitant medication (1; 400mg group)</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1212" spread="350"/>
                    <measurement group_id="O2" value="1298" spread="277"/>
                    <measurement group_id="O3" value="2337" spread="437"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Pharmacokinetic Parameters to Assess Interventions: Cmax</title>
        <description>Cmax: Maximum drug concentration in plasma determined directly from individual concentration-time data</description>
        <time_frame>Day 21</time_frame>
        <population>Post-screening, 30 healthy subjects were randomized into three active drug groups with 8 subjects each and one placebo group with 6 subjects. Between Days 6 and 21, there were 4 (out of 7 total) withdrawals due to inability to follow procedure (2; 250mg and placebo groups), lost to follow-up (1; 400mg group), and adverse event (1; 800mg group)</population>
        <group_list>
          <group group_id="O1">
            <title>ST-246 250 mg</title>
            <description>250 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days.</description>
          </group>
          <group group_id="O2">
            <title>ST-246 400mg</title>
            <description>400 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days.</description>
          </group>
          <group group_id="O3">
            <title>ST-246 800 mg</title>
            <description>800 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo given as a single daily oral dose for 21 days to 6 subjects, to match ST-246 doses (2 patients for each dose equivalent).</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Pharmacokinetic Parameters to Assess Interventions: Cmax</title>
          <description>Cmax: Maximum drug concentration in plasma determined directly from individual concentration-time data</description>
          <population>Post-screening, 30 healthy subjects were randomized into three active drug groups with 8 subjects each and one placebo group with 6 subjects. Between Days 6 and 21, there were 4 (out of 7 total) withdrawals due to inability to follow procedure (2; 250mg and placebo groups), lost to follow-up (1; 400mg group), and adverse event (1; 800mg group)</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1101" spread="378"/>
                    <measurement group_id="O2" value="1457" spread="451"/>
                    <measurement group_id="O3" value="2437" spread="496"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Pharmacokinetic Parameters to Assess Interventions: Tmax</title>
        <description>Tmax: Time to reach maximum drug concentration in plasma calculated from [plasma] versus time profiles.</description>
        <time_frame>Day 1</time_frame>
        <population>Post-screening, 30 healthy subjects were randomized on Day 1 into three active drug groups with 8 subjects each and one placebo group with 6 subjects</population>
        <group_list>
          <group group_id="O1">
            <title>ST-246 250 mg</title>
            <description>250 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days. Blood and urine samples for PK taken on Days 1, 6, and 21.</description>
          </group>
          <group group_id="O2">
            <title>ST-246 400mg</title>
            <description>400 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days. Blood and urine samples for PK taken on Days 1, 6, and 21.</description>
          </group>
          <group group_id="O3">
            <title>ST-246 800 mg</title>
            <description>800 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days. Blood and urine samples for PK taken on Days 1, 6, and 21.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo given as a single daily oral dose to 6 subjects for 21 days, to match ST-246 doses (2 patients for each dose equivalent). Blood and urine samples for PK taken on Days 1, 6, and 21.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Pharmacokinetic Parameters to Assess Interventions: Tmax</title>
          <description>Tmax: Time to reach maximum drug concentration in plasma calculated from [plasma] versus time profiles.</description>
          <population>Post-screening, 30 healthy subjects were randomized on Day 1 into three active drug groups with 8 subjects each and one placebo group with 6 subjects</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="1.1"/>
                    <measurement group_id="O2" value="3.3" spread="1.0"/>
                    <measurement group_id="O3" value="2.9" spread="1.3"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Pharmacokinetic Parameters to Assess Interventions: Tmax</title>
        <description>Tmax: Time to reach maximum drug concentration in plasma calculated from [plasma] versus time profiles.</description>
        <time_frame>Day 6</time_frame>
        <population>Post-screening, 30 healthy subjects were randomized into three active drug groups with 8 subjects each and one placebo group with 6 subjects. By Day 6 there were 3 (out of 7 total) withdrawals from the study due to inability to follow procedure (2; 800mg and placebo groups), and requested due to concomitant medication (1; 400mg group)</population>
        <group_list>
          <group group_id="O1">
            <title>ST-246 250 mg</title>
            <description>250 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days.</description>
          </group>
          <group group_id="O2">
            <title>ST-246 400mg</title>
            <description>400 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days.</description>
          </group>
          <group group_id="O3">
            <title>ST-246 800 mg</title>
            <description>800 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo given as a single daily oral dose for 21 days to 6 subjects, to match ST-246 doses (2 patients for each dose equivalent).</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Pharmacokinetic Parameters to Assess Interventions: Tmax</title>
          <description>Tmax: Time to reach maximum drug concentration in plasma calculated from [plasma] versus time profiles.</description>
          <population>Post-screening, 30 healthy subjects were randomized into three active drug groups with 8 subjects each and one placebo group with 6 subjects. By Day 6 there were 3 (out of 7 total) withdrawals from the study due to inability to follow procedure (2; 800mg and placebo groups), and requested due to concomitant medication (1; 400mg group)</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="1.2"/>
                    <measurement group_id="O2" value="3.7" spread="2.1"/>
                    <measurement group_id="O3" value="3.6" spread="2.3"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Pharmacokinetic Parameters to Assess Interventions: Tmax</title>
        <description>Tmax: Time to reach maximum drug concentration in plasma calculated from [plasma] versus time profiles.</description>
        <time_frame>Day 21</time_frame>
        <population>Post-screening, 30 healthy subjects were randomized into three active drug groups with 8 subjects each and one placebo group with 6 subjects. Between Days 6 and 21, there were 4 (out of 7 total) withdrawals due to inability to follow procedure (2; 250mg and placebo groups), lost to follow-up (1; 400mg group), and adverse event (1; 800mg group)</population>
        <group_list>
          <group group_id="O1">
            <title>ST-246 250 mg</title>
            <description>250 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days.</description>
          </group>
          <group group_id="O2">
            <title>ST-246 400mg</title>
            <description>400 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days.</description>
          </group>
          <group group_id="O3">
            <title>ST-246 800 mg</title>
            <description>800 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo given as a single daily oral dose for 21 days to 6 subjects, to match ST-246 doses (2 patients for each dose equivalent).</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Pharmacokinetic Parameters to Assess Interventions: Tmax</title>
          <description>Tmax: Time to reach maximum drug concentration in plasma calculated from [plasma] versus time profiles.</description>
          <population>Post-screening, 30 healthy subjects were randomized into three active drug groups with 8 subjects each and one placebo group with 6 subjects. Between Days 6 and 21, there were 4 (out of 7 total) withdrawals due to inability to follow procedure (2; 250mg and placebo groups), lost to follow-up (1; 400mg group), and adverse event (1; 800mg group)</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="1.1"/>
                    <measurement group_id="O2" value="2.7" spread="1.0"/>
                    <measurement group_id="O3" value="3.2" spread="1.3"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Pharmacokinetic Parameters to Assess Interventions: t½</title>
        <description>t½: Observed terminal elimination half-life determined after the last dose on Day 21</description>
        <time_frame>Day 21</time_frame>
        <population>Post-screening, 30 healthy subjects were randomized into three active drug groups with 8 subjects each and one placebo group with 6 subjects. Between Days 6 and 21, there were 4 (out of 7 total) withdrawals due to inability to follow procedure (2; 250mg and placebo groups), lost to follow-up (1; 400mg group), and adverse event (1; 800mg group).</population>
        <group_list>
          <group group_id="O1">
            <title>ST-246 250 mg</title>
            <description>250 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days. Blood and urine samples for PK taken on Days 1, 6, and 21.</description>
          </group>
          <group group_id="O2">
            <title>ST-246 400mg</title>
            <description>400 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days. Blood and urine samples for PK taken on Days 1, 6, and 21.</description>
          </group>
          <group group_id="O3">
            <title>ST-246 800 mg</title>
            <description>800 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days. Blood and urine samples for PK taken on Days 1, 6, and 21.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo given as a single daily oral dose to 6 subjects for 21 days, to match ST-246 doses (2 patients for each dose equivalent). Blood and urine samples for PK taken on Days 1, 6, and 21.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Pharmacokinetic Parameters to Assess Interventions: t½</title>
          <description>t½: Observed terminal elimination half-life determined after the last dose on Day 21</description>
          <population>Post-screening, 30 healthy subjects were randomized into three active drug groups with 8 subjects each and one placebo group with 6 subjects. Between Days 6 and 21, there were 4 (out of 7 total) withdrawals due to inability to follow procedure (2; 250mg and placebo groups), lost to follow-up (1; 400mg group), and adverse event (1; 800mg group).</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8" spread="10.4"/>
                    <measurement group_id="O2" value="19.9" spread="8.9"/>
                    <measurement group_id="O3" value="20.7" spread="8.4"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Pharmacokinetic Parameters to Assess Interventions: AUCtau</title>
        <description>AUCtau: Area under the plasma concentration-time curve for each dosing interval (from time 0 to 24 hours sample) determined using the linear trapezoidal rule</description>
        <time_frame>Day 1</time_frame>
        <population>Post-screening, 30 healthy subjects were randomized on Day 1 into three active drug groups with 8 subjects each and one placebo group with 6 subjects</population>
        <group_list>
          <group group_id="O1">
            <title>ST-246 250 mg</title>
            <description>250 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days. Blood and urine samples for PK taken on Days 1, 6, and 21.</description>
          </group>
          <group group_id="O2">
            <title>ST-246 400mg</title>
            <description>400 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days. Blood and urine samples for PK taken on Days 1, 6, and 21.</description>
          </group>
          <group group_id="O3">
            <title>ST-246 800 mg</title>
            <description>800 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days. Blood and urine samples for PK taken on Days 1, 6, and 21.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo given as a single daily oral dose to 6 subjects for 21 days, to match ST-246 doses (2 patients for each dose equivalent). Blood and urine samples for PK taken on Days 1, 6, and 21.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Pharmacokinetic Parameters to Assess Interventions: AUCtau</title>
          <description>AUCtau: Area under the plasma concentration-time curve for each dosing interval (from time 0 to 24 hours sample) determined using the linear trapezoidal rule</description>
          <population>Post-screening, 30 healthy subjects were randomized on Day 1 into three active drug groups with 8 subjects each and one placebo group with 6 subjects</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9101" spread="3492"/>
                    <measurement group_id="O2" value="13146" spread="3626"/>
                    <measurement group_id="O3" value="20959" spread="6091"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Pharmacokinetic Parameters to Assess Interventions: AUCtau</title>
        <description>AUCtau: Area under the plasma concentration-time curve for each dosing interval (from time 0 to 24 hours sample) determined using the linear trapezoidal rule</description>
        <time_frame>Day 6</time_frame>
        <population>Post-screening, 30 healthy subjects were randomized into three active drug groups with 8 subjects each and one placebo group with 6 subjects. By Day 6 there were 3 (out of 7 total) withdrawals from the study due to inability to follow procedure (2; 800mg and placebo groups), and requested due to concomitant medication (1; 400mg group)</population>
        <group_list>
          <group group_id="O1">
            <title>ST-246 250 mg</title>
            <description>250 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days.</description>
          </group>
          <group group_id="O2">
            <title>ST-246 400mg</title>
            <description>400 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days.</description>
          </group>
          <group group_id="O3">
            <title>ST-246 800 mg</title>
            <description>800 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo given as a single daily oral dose for 21 days to 6 subjects, to match ST-246 doses (2 patients for each dose equivalent).</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Pharmacokinetic Parameters to Assess Interventions: AUCtau</title>
          <description>AUCtau: Area under the plasma concentration-time curve for each dosing interval (from time 0 to 24 hours sample) determined using the linear trapezoidal rule</description>
          <population>Post-screening, 30 healthy subjects were randomized into three active drug groups with 8 subjects each and one placebo group with 6 subjects. By Day 6 there were 3 (out of 7 total) withdrawals from the study due to inability to follow procedure (2; 800mg and placebo groups), and requested due to concomitant medication (1; 400mg group)</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11892" spread="4389"/>
                    <measurement group_id="O2" value="15432" spread="4708"/>
                    <measurement group_id="O3" value="23352" spread="4696"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Pharmacokinetic Parameters to Assess Interventions: AUCtau</title>
        <description>AUCtau: Area under the plasma concentration-time curve for each dosing interval (from time 0 to 24 hours sample) determined using the linear trapezoidal rule</description>
        <time_frame>Day 21</time_frame>
        <population>Post-screening, 30 healthy subjects were randomized into three active drug groups with 8 subjects each and one placebo group with 6 subjects. Between Days 6 and 21, there were 4 (out of 7 total) withdrawals due to inability to follow procedure (2; 250mg and placebo groups), lost to follow-up (1; 400mg group), and adverse event (1; 800mg group).</population>
        <group_list>
          <group group_id="O1">
            <title>ST-246 250 mg</title>
            <description>250 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days.</description>
          </group>
          <group group_id="O2">
            <title>ST-246 400mg</title>
            <description>400 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days.</description>
          </group>
          <group group_id="O3">
            <title>ST-246 800 mg</title>
            <description>800 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo given as a single daily oral dose for 21 days to 6 subjects, to match ST-246 doses (2 patients for each dose equivalent).</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Pharmacokinetic Parameters to Assess Interventions: AUCtau</title>
          <description>AUCtau: Area under the plasma concentration-time curve for each dosing interval (from time 0 to 24 hours sample) determined using the linear trapezoidal rule</description>
          <population>Post-screening, 30 healthy subjects were randomized into three active drug groups with 8 subjects each and one placebo group with 6 subjects. Between Days 6 and 21, there were 4 (out of 7 total) withdrawals due to inability to follow procedure (2; 250mg and placebo groups), lost to follow-up (1; 400mg group), and adverse event (1; 800mg group).</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10083" spread="2843"/>
                    <measurement group_id="O2" value="16182" spread="5534"/>
                    <measurement group_id="O3" value="22684" spread="4579"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Pharmacokinetic Parameters to Assess Interventions: Ae(0-24)</title>
        <description>Ae(0-24): Cumulative amount of drug excreted unchanged in urine over 24 hours (three 8-hour collection periods), determined on Days 1 and 21</description>
        <time_frame>Day 1</time_frame>
        <population>Post-screening, 30 healthy subjects were randomized on Day 1 into three active drug groups with 8 subjects each and one placebo group with 6 subjects</population>
        <group_list>
          <group group_id="O1">
            <title>ST-246 250 mg</title>
            <description>250 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days. Blood and urine samples for PK taken on Days 1, 6, and 21.</description>
          </group>
          <group group_id="O2">
            <title>ST-246 400mg</title>
            <description>400 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days. Blood and urine samples for PK taken on Days 1, 6, and 21.</description>
          </group>
          <group group_id="O3">
            <title>ST-246 800 mg</title>
            <description>800 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days. Blood and urine samples for PK taken on Days 1, 6, and 21.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo given as a single daily oral dose to 6 subjects for 21 days, to match ST-246 doses (2 patients for each dose equivalent). Blood and urine samples for PK taken on Days 1, 6, and 21.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Pharmacokinetic Parameters to Assess Interventions: Ae(0-24)</title>
          <description>Ae(0-24): Cumulative amount of drug excreted unchanged in urine over 24 hours (three 8-hour collection periods), determined on Days 1 and 21</description>
          <population>Post-screening, 30 healthy subjects were randomized on Day 1 into three active drug groups with 8 subjects each and one placebo group with 6 subjects</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.041" spread="0.031"/>
                    <measurement group_id="O2" value="0.110" spread="0.066"/>
                    <measurement group_id="O3" value="0.157" spread="0.048"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Pharmacokinetic Parameters to Assess Interventions: Ae(0-24)</title>
        <description>Ae(0-24): Cumulative amount of drug excreted unchanged in urine over 24 hours (three 8-hour collection periods), determined on Days 1 and 21</description>
        <time_frame>Day 21</time_frame>
        <population>Post-screening, 30 healthy subjects were randomized into three active drug groups with 8 subjects each and one placebo group with 6 subjects. Between Days 6 and 21, there were 4 (out of 7 total) withdrawals due to inability to follow procedure (2; 250mg and placebo groups), lost to follow-up (1; 400mg group), and adverse event (1; 800mg group).</population>
        <group_list>
          <group group_id="O1">
            <title>ST-246 250 mg</title>
            <description>250 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days.</description>
          </group>
          <group group_id="O2">
            <title>ST-246 400mg</title>
            <description>400 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days.</description>
          </group>
          <group group_id="O3">
            <title>ST-246 800 mg</title>
            <description>800 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo given as a single daily oral dose for 21 days to 6 subjects, to match ST-246 doses (2 patients for each dose equivalent).</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Pharmacokinetic Parameters to Assess Interventions: Ae(0-24)</title>
          <description>Ae(0-24): Cumulative amount of drug excreted unchanged in urine over 24 hours (three 8-hour collection periods), determined on Days 1 and 21</description>
          <population>Post-screening, 30 healthy subjects were randomized into three active drug groups with 8 subjects each and one placebo group with 6 subjects. Between Days 6 and 21, there were 4 (out of 7 total) withdrawals due to inability to follow procedure (2; 250mg and placebo groups), lost to follow-up (1; 400mg group), and adverse event (1; 800mg group).</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.049" spread="0.026"/>
                    <measurement group_id="O2" value="0.108" spread="0.046"/>
                    <measurement group_id="O3" value="0.213" spread="0.165"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 weeks</time_frame>
      <desc>Study drug was administered to each dosing group cohort for 21 days and subjects were followed for an additional 30 to 32 days. AEs were recorded throughout this time period.</desc>
      <group_list>
        <group group_id="E1">
          <title>ST-246 250 mg</title>
          <description>250 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days.</description>
        </group>
        <group group_id="E2">
          <title>ST-246 400mg</title>
          <description>400 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days. Blood and urine samples for PK taken on Days 1, 6, and 21.</description>
        </group>
        <group group_id="E3">
          <title>ST-246 800 mg</title>
          <description>800 mg ST-246 given as a single daily oral dose to 8 subjects for 21 days. Blood and urine samples for PK taken on Days 1, 6, and 21.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo given as a single daily oral dose for 21 days to 6 subjects, to match ST-246 doses (2 patients for each dose equivalent). Blood and urine samples for PK taken on Days 1, 6, and 21.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal Eye Sensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hand Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Procedural Complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Backpain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Only one subject, in the 800mg group, experienced a severe headache (TEAE of Grade 3; deemed study-drug related) on Day 15, and discontinued the study.</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI must obtain the sponsor's written consent to publish any study results and must notify the sponsor within 30 working days prior to publishing.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Annie Frimm, Vice President, Regulatory Affairs</name_or_title>
      <organization>SIGA Technologies, Inc.</organization>
      <phone>951-303-8797</phone>
      <email>afrimm@siga.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

